HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With $1.9 Bil. Bid For Chattem, Sanofi Knocks On Door To U.S. OTC Market

This article was originally published in The Rose Sheet

Executive Summary

With its $1.9 billion bid for personal-care and over-the-counter drug manufacturer Chattem, French pharmaceutical giant Sanofi-Aventis stands to gain a toehold in the sizeable U.S. consumer health sector and beef up its presence in emerging markets

You may also be interested in...



Sanofi Looks To Climb Consumer Ladder In Boehringer Business Swap

A pending agreement includes a $5.2bn cash payment from Boehringer to Sanofi but excludes Boehringer’s consumer product business in China. The brands Sanofi will add to its consumer health lineup include two marketed in the US, Dulcolax constipation relief and Zantac heartburn remedy.

Sanofi Looks To Climb Consumer Ladder In Boehringer Business Swap

A pending agreement includes a $5.2bn cash payment from Boehringer to Sanofi but excludes Boehringer’s consumer product business in China. The brands Sanofi will add to its consumer health lineup include two marketed in the US, Dulcolax constipation relief and Zantac heartburn remedy.

Sanofi Mulls Putting Cash Behind Interest In Buying L’Oreal’s Shares

Sanofi has the cash to buy back about $12 billion of its shares currently owned by beauty firm L’Oreal, if those shares were up for sale, Sanofi CEO Viehbacher says. L’Oreal CEO Agon suggested in recent earnings call that the firm could seek cash for future deals through the sale of its 9% stake in Sanofi.

Related Content

UsernamePublicRestriction

Register

RS016647

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel